KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
The first multiple center prospective study of rhFSH CTP in patients undergoing assisted reproductive technology in China. PMID 39837901 · Sci Rep · 2025-Jan-21 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Past, present, and future of Phase 3 vaccine trial design: rethinking statistics for the 21st century. PMID 39570146 · Clin Exp Immunol · 2025-Jan-21 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
[Application Research of Narrative Care to the Management of Symptom Clusters and Post-traumatic Growth in Patients Undergoing Lung Cancer Surgery]. PMID 39988438 · Zhongguo Fei Ai Za Zhi · 2025-Jan-20 The study is a randomized controlled trial in human lung cancer surgery patients, but it evaluates a non-drug nursing intervention (narrative care) for symptom clusters and post-traumatic growth, not a drug-containing intervention. It reports only patient-reported outcome measures (anxiety, sleep, quality of life, post-traumatic growth) at specific time points, without any time-to-event efficacy endpoints. The trial phase is not specified in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Systematic Review and Network Meta-Analysis on Treating Hormone Receptor-Positive Metastatic Breast Cancer After CDK4/6 Inhibitors. PMID 39851969 · Curr Oncol · 2025-Jan-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2. PMID 39833722 · BMC Cancer · 2025-Jan-20 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Controlled ovarian hyperstimulation with or without letrozole for fertility preservation in breast cancer patients: study protocol for a randomised controlled trial. PMID 39832986 · BMJ Open · 2025-Jan-20 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A comparative study between central quadrantectomy and nipple resection with areola preservation Versus Grisotti flap mammoplasty in central breast lesions extending to nipple: a randomized clinical trial. PMID 39828867 · J Egypt Natl Canc Inst · 2025-Jan-20 The study is an oncology randomized trial with primary results, but it does not meet the eligibility criteria because it lacks a specified Phase III/II/IIIb designation, involves a non-drug (surgical) intervention only, and does not report a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish. PMID 39432867 · J Clin Oncol · 2025-Jan-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors. PMID 39411812 · J Clin Oncol · 2025-Jan-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01. PMID 39265124 · J Clin Oncol · 2025-Jan-20 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 2 Figure · 3 Panel · risk unclear
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. PMID 39250535 · J Clin Oncol · 2025-Jan-20 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 2 Figure · 6 Panel · risk unclear
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. PMID 39798579 · Lancet · 2025-Jan-18 命中用户提供的消化道肿瘤阳性参考集。
H L S B
旧组与严格 v3 交集 eligiblepositive_reference needs_review 1 Figure · 2 Panel · risk unclear
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. PMID 39798578 · Lancet · 2025-Jan-18 命中用户提供的消化道肿瘤阳性参考集。
H L S B
旧组与严格 v3 交集 eligiblepositive_reference needs_review 0 Figure · 0 Panel · risk not_assessed
Artificial Intelligence for Adenoma and Polyp Detection During Screening and Surveillance Colonoscopy: A Randomized-Controlled Trial. PMID 39860586 · J Clin Med · 2025-Jan-17 The study is excluded because it is not a drug intervention trial (it compares an AI-assisted colonoscopy system to standard colonoscopy) and does not report a time-to-event efficacy endpoint required for Kaplan-Meier digitization. While it is an oncology-related RCT in humans, it fails the key criteria of drug intervention and time-to-event outcome.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction. PMID 39846984 · Oncologist · 2025-Jan-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Esketamine nasal spray versus quetiapine XR in adults with treatment-resistant depression: a secondary analysis of the ESCAPE-TRD randomized clinical trial. PMID 39819527 · CNS Spectr · 2025-Jan-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Hydroxychloroquine in combination with platinum doublet chemotherapy as first-line treatment for extensive-stage small cell lung cancer (Study 15): A randomised phase II multicentre trial. PMID 39693892 · Eur J Cancer · 2025-Jan-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The modified Glasgow Prognostic Score (mGPS) can guide decisions for immunotherapy treatment beyond progression. PMID 39662097 · Eur J Cancer · 2025-Jan-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer. PMID 39576210 · Clin Cancer Res · 2025-Jan-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial. PMID 39540844 · Clin Cancer Res · 2025-Jan-17 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 1 Panel · risk unclear
Endoscopic sphincterotomy to prevent post-ERCP pancreatitis after self-expandable metal stent placement for distal malignant biliary obstruction (SPHINX): a multicentre, randomised controlled trial. PMID 39389757 · Gut · 2025-Jan-17 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
A Community Health Worker-driven and integrated interactive text messaging intervention to promote smoking cessation and lung cancer screening uptake rates among high-risk Asian immigrants: a feasibility pilot RCT study. PMID 40471875 · Transl Behav Med · 2025-Jan-16 The study is a randomized feasibility pilot of a behavioral and community health intervention for smoking cessation and lung cancer screening uptake. It is not a Phase III/IIIb or Phase II/III drug intervention trial, and it does not report a primary or key secondary time-to-event efficacy endpoint (such as OS, PFS, DFS) with Kaplan-Meier analysis or hazard ratio. The focus is on feasibility, acceptability, and process outcomes (e.g., screening completion rates), not a definitive efficacy trial for a drug.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of Lemborexant on Daytime Functioning in Adults With Insomnia: Patient-Reported Outcomes From a Phase 3 Clinical Trial. PMID 39823487 · Prim Care Companion CNS Disord · 2025-Jan-16 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Lerociclib plus fulvestrant in patients with HR+/HER2- locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial. PMID 39820749 · Nat Commun · 2025-Jan-16 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type no_km 0 Figure · 0 Panel · risk not_applicable
Supporting community translation of lung cancer screening: A web-based decision aid to support informed decision making. PMID 39817729 · Transl Behav Med · 2025-Jan-16 The study is a randomized feasibility/acceptability trial of a decision aid for lung cancer screening. While oncology-related and randomized, it is not a Phase III/IIIb or Phase II/III trial with a drug intervention and a primary time-to-event efficacy endpoint (e.g., OS, PFS). The primary outcomes are feasibility metrics, not survival or progression endpoints.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer. PMID 39813643 · N Engl J Med · 2025-Jan-16 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Improving Neck and Jawline Aesthetics With OnabotulinumtoxinA by Minimizing Platysma Muscle Contraction Effects: Efficacy and Safety Results in a Phase 3 Randomized, Placebo-Controlled Study. PMID 39475141 · Aesthet Surg J · 2025-Jan-16 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study. PMID 39331724 · Blood · 2025-Jan-16 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 2 Panel · risk unclear
Effect of Continuous Infusion Therapy With Low-dose Terlipressin Combined With Norepinephrine on Hemodynamics, Inflammatory Markers, and Prognosis in Patients With Severe Septic Shock. PMID 39091078 · Mil Med · 2025-Jan-16 The study is a randomized trial with drug interventions and original results, but it is not an oncology study and does not report a primary time-to-event efficacy endpoint (e.g., overall survival, progression-free survival).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cost-effectiveness analysis of eribulin versus dacarbazine in patients with advanced liposarcoma. PMID 39814865 · Sci Rep · 2025-Jan-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. PMID 39814420 · BMJ · 2025-Jan-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Observation on the efficacy of TPO receptor agonists and platelet transfusion in chemotherapy-induced thrombocytopenia in malignant tumors. PMID 39810144 · World J Surg Oncol · 2025-Jan-15 The record describes a randomized study of a TPO receptor agonist and platelet transfusion for chemotherapy-induced thrombocytopenia in cancer patients. While it is a randomized, oncology-related, human study with a drug intervention (avatrombopag) and reports original results, it fails two key eligibility criteria. First, the phase is not specified as Phase III/IIIb or Phase II/III; the publication type 'Randomized Controlled Trial' does not establish a definitive phase, and no phase is mentioned in the title, abstract, or metadata. Second, the primary endpoints are platelet counts, recovery times, cytokine levels, and coagulation indices—all short-term, laboratory-based outcomes. There is no mention of a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or any Kaplan-Meier analysis or hazard ratio for a time-to-event outcome.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term changes in carotid intima-media thickness according to baseline blood pressure level: J-STARS Echo study. PMID 39673820 · J Neurol Sci · 2025-Jan-15 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Randomized clinical trial of a digital integrative medicine intervention among patients undergoing active cancer treatment. PMID 39809874 · NPJ Digit Med · 2025-Jan-14 The study is a randomized Phase III trial in oncology, but the intervention is non-drug (digital integrative medicine) and the endpoints are symptom/quality-of-life measures and healthcare utilization, not time-to-event efficacy outcomes.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
First-line systemic therapy and sequencing options in advanced biliary tract cancer: A systematic review and network meta-analysis. PMID 39647857 · Biosci Trends · 2025-Jan-14 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure. PMID 39340828 · Circulation · 2025-Jan-14 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Echocardiographic phenotypes of diabetic myocardial disorder: evolution over 15 months follow-up in the ARISE-HF trial. PMID 39806375 · Cardiovasc Diabetol · 2025-Jan-13 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer. PMID 39800716 · Signal Transduct Target Ther · 2025-Jan-13 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 2 Figure · 2 Panel · risk unclear
Assessment and reporting of extraintestinal manifestations and fatigue in phase 3 inflammatory bowel disease clinical trials. PMID 39825757 · J Crohns Colitis · 2025-Jan-11 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies. PMID 39804294 · J Crohns Colitis · 2025-Jan-11 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Young, Empowered & strong (YES): a study protocol paper for a randomized controlled trial of an mHealth symptom monitoring and self-management intervention for adolescent and young adult (AYA) breast cancer survivors. PMID 39799291 · BMC Public Health · 2025-Jan-11 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Obtaining personalized predictions from a randomized controlled trial on Alzheimer's disease. PMID 39799207 · Sci Rep · 2025-Jan-11 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Phase III Evaluation of Treatment Combinations in Three-Arm Trials. PMID 39467219 · J Clin Oncol · 2025-Jan-10 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial. PMID 39389055 · Med · 2025-Jan-10 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial Comparing Simple Versus Radical Hysterectomy. PMID 39353164 · J Clin Oncol · 2025-Jan-10 This is a phase III randomized trial in oncology (low-risk cervical cancer) reporting original results. However, it does not meet two mandatory criteria: (1) the intervention is purely surgical (simple vs. radical hysterectomy) with no drug-containing arm, and (2) the primary outcomes reported are sexual health and quality of life (patient-reported outcomes), not a time-to-event efficacy endpoint such as overall survival, progression-free survival, or recurrence-free survival with Kaplan-Meier or hazard ratio analysis.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Roxadustat for Anemia in Patients Receiving Chemotherapy for Nonmyeloid Malignancies: A Randomized, Open-Label, Active-Controlled Phase III Study. PMID 39353163 · J Clin Oncol · 2025-Jan-10 While the record describes an oncology, human, randomized, Phase III trial with a drug intervention and original results, it does not have a primary or key secondary time-to-event efficacy endpoint as required for inclusion in the KM digitization cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial. PMID 39303200 · J Clin Oncol · 2025-Jan-10 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 2 Figure · 4 Panel · risk unclear
Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML. PMID 39298738 · J Clin Oncol · 2025-Jan-10 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 3 Panel · risk unclear
Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial. PMID 39788967 · Nat Commun · 2025-Jan-09 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Randomized Controlled Trial to Compare AmnioExcel Human Amniotic Allograft in Weekly Versus Biweekly Treatment of Diabetic Foot Ulcers. PMID 39784000 · Int J Low Extrem Wounds · 2025-Jan-09 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -